Anti-PD-1 therapy triggers Tfh cell-dependent IL-4 release to boost CD8 T cell responses in tumor-draining lymph nodes.

Authors:
Ruggiu M; Guérin MV; Corre B; Bardou M; Alonso R and 7 more

Journal:
J Exp Med

Publication Year: 2024

DOI:
10.1084/jem.20232104

PMCID:
PMC10901238

PMID:
38417020

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Exp Med

Abbreviation: J Exp Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Addendum: Resolvins suppress tumor growth and enhance cancer therapy.
Sulciner ML; Serhan CN; Gilligan MM and 18 more (2024) - Transparency Score: 2/6
Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children.
Bastard P; Gervais A; Taniguchi M and 87 more (2024) - Transparency Score: 3/6
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy.
Wang L; Xiao Y; Luo Y and 19 more (2024) - Transparency Score: 5/6
The effector program of human CD8 T cells supports tissue remodeling.
Delacher M; Schmidleithner L; Simon M and 32 more (2024) - Transparency Score: 4/6
A cell-free antigen processing system informs HIV-1 epitope selection and vaccine design.
Sengupta S; Zhang J; Reed MC and 15 more (2023) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosures: The authors declare no competing interests exist."

Evidence found in paper:

"The work was supported by Institut Pasteur, Institut National de la Santé et de la Recherche Médicale, an Advanced grant (ENLIGHTEN) from the European Research Council (P. Bousso), and by the Investissements d’Avenir program managed by the Agence Nationale de la Recherche (ANR-10-LABX-77-01). M. Ruggiu was supported by a fellowship from Basic and Translational Research Training Programme Aviesan ITMO Cancer. M.V. Guérin was supported by Fondation ARC."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025